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Combining TGF-b inhibition and angiotensin II blockade results
in enhanced antifibrotic effect
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Combining TGF-b inhibition and angiotensin II blockade re-
sults in enhanced antifibrotic effects.
Background. Although angiotensin II (Ang II) blockade is
rapidly becoming standard antifibrotic therapy in renal diseases,
current data suggest that Ang II blockade alone cannot stop
fibrotic disease. New therapies, such as antibodies to trans-
forming growth factor-b (TGF-b), or drug combinations will be
required to further slow or halt disease progression. Here, us-
ing the anti-Thy1 model of glomerulonephritis, the maximally
therapeutic dose of the TGF-b neutralizing mouse monoclonal
antibody (1D11) was determined and compared with the maxi-
mally effective dose of enalapril. Then, the effect of combining
both treatments at maximal doses was determined.
Methods. After disease induction with the anti-Thy1 anti-
body, OX-7, increasing doses of 1D11 were given intraperi-
toneally (IP) on days 1, 3, and 5. Enalapril was administered in
drinking water from day 1. The fibrotic response was assessed
at day 6.
Results. 1D11 dose-dependently reduced fibrosis, with the
0.5 and 5 mg/kg doses showing maximal therapeutic effects,
reducing period-acid Schiff (PAS) staining by 56% and 45%,
respectively. Fibronectin and collagen I staining was reduced
by 32% to 36%, respectively. Glomerular mRNA and produc-
tion of fibronectin, plasminogen activator inhibitor-1 (PAI-1),
TGF-b1, and p-Smad2 protein were also reduced. The maximal
therapeutic effects of 1D11 and enalapril alone were very sim-
ilar. However, combination therapy led to further reduction in
disease. Notably, matrix deposition was reduced by 80%.
Conclusion. While 1D11 or enalapril at maximal doses reduce
fibrosis equally, simultaneous blockade of Ang II and TGF-b
reduces fibrotic disease considerably more, offering hope that
such drug combinations may confer a therapeutic advantage
over angiotensin blockade alone.
In recent years, the number of patients developing end-
stage renal disease (ESRD) has dramatically increased
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worldwide [1]. Slowing or stopping the progression to
ESRD is the biggest challenge facing nephrologists today.
Progressive accumulation of extracellular matrix (ECM)
in glomeruli and interstitium characterizes chronic re-
nal disease, regardless of the underlying etiology [2, 3].
This points to a final common pathway for ESRD. Iden-
tification of key mediators of matrix accumulation and
development of strategies to block the action of these
mediators is now the focus of many investigators. Two
of these key mediators are angiotensin II (Ang II) and
transforming growth factor-b (TGF-b).
Blockade of Ang II significantly limits renal matrix ex-
pansion in numerous experimental models of acute and
chronic renal disease [4], indicating that Ang II is a central
effector in the pathogenesis of renal fibrosis. Although
angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin II type I receptor antagonists (AT1RAs) have
been remarkably successful in clinical trials [5–12], their
full therapeutic potential in humans may not have yet
been realized because of inadequate dosing. Nonethe-
less, from work with animal models [13] and the overall
clinical experience, it appears unlikely that these drugs
alone will entirely halt fibrosis at any dose. A promising
and perhaps necessary approach to further disease re-
duction is combination of new antifibrotic therapies with
inhibitors of the renin-angiotensin system.
Of an increasing number of therapies showing efficacy
in animal studies, neutralizing antibodies to TGF-b are
the most thoroughly studied. From the first studies pub-
lished in 1990 demonstrating TGF-b’s fibrogenic effects
[14–16], overwhelming evidence now exists that sustained
over-expression of TGF-b is a key mediator of fibrotic
disease. Its fibrogenic actions include: (1) stimulation of
matrix synthesis; (2) inhibition of matrix degradation; and
(3) modulation of matrix receptor expression to facilitate
cell-matrix interactions. Many strategies to block TGF-b
have been used in animal studies. TGF-b antibodies, anti-
sense oligonucleotides [17, 18], soluble TGF-b type II re-
ceptor [19] or type III receptor [20], the TGF-b inhibitor
decorin [21, 22], TGF-b’s latency-associated peptide [23],
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the negative regulatory signaling molecule Smad7 [24],
and inhibition of TGF-b activation [25] have all shown
therapeutic efficacy. Among these strategies, TGF-b an-
tibodies are the best developed and most thoroughly
studied. Many in vivo studies have demonstrated their
antifibrotic effects in renal fibrosis [16, 26–30], pulmonary
fibrosis [31], arterial restenosis [32], and skin scarring and
thickening [33–35]. Long-term TGF-b antibody treat-
ment has so far been shown to be safe and to effectively
prevent glomerulosclerosis in a mouse model of type 2
diabetes [27]. In addition, advances in antibody technol-
ogy now make production of totally human antibodies
a reality, enhancing their clinical utility as therapeutics.
To date, however, there are no animal experiments de-
signed to answer three important questions: how much
disease reduction is possible with these antibodies; how
does this disease reduction compare side-by-side with
Ang II blockade alone; and can disease reduction be in-
creased if maximally effective doses of both drugs are
combined.
Here we used the model of acute glomerulonephritis
induced by injection of an anti-Thy1 antibody to investi-
gate the potential of different doses of the mouse anti–
TGF-b1, -b2, and -b3 monoclonal antibody, 1D11, to re-
duce disease. We then compared the maximally effective
dose of 1D11 with the previously determined maximally
effective dose of the ACEI, enalapril. Finally, we deter-
mined whether combination of the antibody and enalapril
at maximally therapeutic doses could further reduce
disease.
METHODS
Materials
The anti–TGF-b antibody, 1D11, which neutralizes
isoforms TGF-b1, -b2, and -b3, was kindly provided
by Cambridge Antibody Technology (Granta Park;
Cambridgeshire, UK) and Genzyme Corporation
(Cambridge, MA, USA).
Unless otherwise indicated, materials, chemicals, or
culture media were purchased from Sigma Chemical Co
(St. Louis, MO, USA).
Animals
The studies were performed on male Sprague Daw-
ley rats (200 to 250 g) obtained from the Sasco colony
of Charles River Laboratories (Wilmington, MA, USA).
Animal housing and care were in accordance with the
National Institutes of Health Guide for the Care and
Use of Laboratory Animals, NIH publication no. 85–23,
1985. Animals were fed a normal protein diet (22% pro-
tein, Teklad No. 86 550; Teklad Premier Laboratory Diets,
Madison, WI, USA). Glomerulonephritis was induced by
tail vein injection of 2.25 mg/kg of the monoclonal anti-
Thy 1.1 antibody OX-7 (NCCC; Biovest International,
Table 1. Experimental design
Group Treatment and (days of treatment) Designation
1 PBS IV (0) Normal control (NC)
2 OX7 IV (0), PBS IP (1, 3, and 5) Disease control (DC)
3 OX7 IV (0), 1D11, 0.01 mg/kg IP (1,
3, and 5)
Ab 0.01
4 OX7 IV (0), 1D11, 0.1 mg/kg IP (1,
3, and 5)
Ab 0.1
5 OX7 IV (0), 1D11, 0.5 mg/kg IP (1,
3, and 5)
Ab 0.5
6 OX7 IV (0), 1D11, 5 mg/kg IP (1, 3,
and 5)
Ab 5.0
7 OX7 IV (0), enalapril 200 mg/L in
the drinking water (1–6)
Enal
8 OX7 IV (0), enalapril 200 mg/L in
the drinking water (1–6), 1D11
0.5 mg/kg IP (1, 3, and 5)
Enal + Ab 0.5
9 OX7 IV (0), enalapril 200 mg/L in
the drinking water, 1D11 5 mg/kg
IP (1, 3, and 5)
Enal + Ab 5.0
10 OX7 IV (0), 13C4 (Control
antibody), 5 mg/kg IP (1, 3, and 5)
Control Ab
Inc., Minneapolis, MN, USA). OX-7 binds to a Thy 1-
like epitope on the surface of mesangial cells, causing
complement-dependent cell lysis followed by fibrotic tis-
sue repair [36]. Control animals were injected with similar
volumes of phosphate-buffered saline (PBS).
Experimental design
A pilot experiment was carried out to determine the ef-
fective dose range of 1D11 in anti-Thy 1 glomerulonephri-
tis. Doses of 1D11 from 0.05 to 5 mg/kg were administered
to 10 groups of 4 rats. Based on the results, a larger ex-
periment was carried out.
Groups of 8 rats were assigned and treated as outlined
in Table 1. We have previously published that doses of
enalapril above 100 mg/mL in drinking water are maxi-
mally effective in this model [13]. A dose of 200 mg/mL
enalapril was used here. Enalapril treatment began
24 hours after disease induction. At that time, based on an
average water intake of 40 mL per day, 60% of the daily
dose was administered by gavage as described previously
[13]. The pilot results indicated that the dose response was
in the range 0.01 to 5 mg/kg; 1D11 doses of 0.5 and 5.0 mg/
kg maximally reduced ECM accumulation, so these were
used in combination with enalapril in groups 8 and 9.
Six days after induction of glomerulonephritis the ani-
mals were anesthetized with isoflurane. Following a mid-
line abdominal incision, 5 to 10 mL blood was drawn
from the lower abdominal aorta, and kidneys were subse-
quently perfused with 30 mL ice-cold PBS. For histologic
examination cortical tissue was snap frozen or fixed in
10% neutral buffered formalin. Glomeruli from individ-
ual rats were isolated by a graded sieving technique (150,
125, and 75 lm mesh metal sieves) as described previ-
ously [15], and resuspended at 5000 glomeruli/mL/well
in RPMI supplemented with 0.1 U/mL insulin, 100
U/mL penicillin, 100 lg/mL streptomycin, and 25 mmol/L
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HEPES buffer. After a 48-hour incubation at 37◦C/5%
CO2 the supernatant was harvested and stored at −70◦C
until analysis of glomerular production of fibronectin
(FN), PAI-1, and TGF-b1.
Measurement of FN, PAI-1, and TGF-b1
FN and PAI-1 synthesis were measured with modified
enzyme-linked immunosorbent assay (ELISA) accord-
ing to published methods [37]. TGF-b1 production of
cultured glomeruli was measured after acid-activation us-
ing a commercially available ELISA kit (DuoSet; R&D
Systems, Minneapolis, MN, USA) according to the manu-
facturer’s instructions. Three samples from each rat were
analyzed.
Light microscopy
All microscopic examinations were performed in a
blinded fashion. Three lm sections of paraffin-embedded
tissue were stained with periodic-acid Schiff (PAS), and
glomerular matrix expansion was evaluated as previously
described [15]. Briefly, in 30 glomeruli from each rat, the
percentage of mesangial matrix occupying each glomeru-
lus was rated as 0 = 0%, 1 = 25%, 2 = 50%, 3 = 75%,
and 4 = 100%.
Immunofluorescent staining
Goat antihuman collagen I antibody was obtained
from Southern Biotechnology Associates, Inc. (Birm-
ingham, AL, USA). Fluorescein isothiocyanate (FITC)-
conjugated rabbit antigoat immunoglobulin G (IgG;
Dako Corporation, Carpinteria, CA, USA) was used
as secondary antibody. Monoclonal mouse anticellular
FN EDA+ was obtained from Harlan Sera-Lab, Ltd.
(Loughborough, England). FITC-rat F(ab’)2 antimouse
IgG(H+L) was used as secondary antibody (Jackson Im-
munoresearch, West Grove, PA, USA). FITC-conjugated
mouse antirat monocyte/macrophage antibody (ED1)
was obtained from Serotec (Oxford, UK).
Renal tissue was snap frozen in 2-methylbutane that
had been precooled at −80◦C. Four-lm sections were ob-
tained using a cryostat (Leica CM 1800; E Licht Com-
pany, Denver, CO, USA). Tissues were air dried and
fixed in alcohol, washed in PBS, pH 7.4, incubated with
the primary antibodies, washed with PBS, incubated
with the appropriate FITC-conjugated secondary anti-
bodies, washed again, and mounted with cover glasses
using Fluoromount-G (Southern Biotechnology Asso-
ciates, Inc.).
The intensity of glomerular staining of collagen I
and FN was evaluated according to a 0 to 4 scale,
which has been described in detail previously [38]. The
number of cells per glomerulus staining positive for
the monocyte/macrophage marker ED1 were counted.
Thirty glomeruli per sample were evaluated. The mean
values with standard error values were calculated.
RNA preparation and Northern hybridization
Total RNA was extracted by a guanidinium isoth-
iocyanate method using Trizol Reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. RNA from 8 rats of each group was pooled for
further examination. For Northern analysis, RNA was
denatured and fractionated by electrophoresis through
a 1.0% agarose gel (30 lg/lane) and transferred to a ny-
lon membrane (BrightStarTM-Plus; Ambion, Inc., Austin,
TX, USA). Nucleic acids were immobilized by ultraviolet
irradiation (Stratagene, La Jolla, CA, USA). Membranes
were prehybridized with ULTRAhybTM buffer (Ambion,
Inc.), and hybridized with DNA probes labeled with
32P-dATP by random oligonucleotide priming (Strip-EZ
DNATM; Ambion, Inc.). The blots were washed in 2 ×
standard saline citrate (SSC), 0.1% sodium dodecyl sul-
fate (SDS) at room temperature for 10 minutes and in 0.1
× SSC, 0.1% SDS at 42◦C for 15 minutes 2 times. DNA
probes used were: (1) mouse 18S (ATCC, Manassas, VA,
USA); (2) rat procollagen a1 cDNA (kindly provided by
Dr. D. Rowe) [39]; (3) FN-EDA cDNA (kindly provided
by Dr. R.O. Hynes) [40]; (4) PAI-1 cDNA (kindly pro-
vided by Dr. T.D. Gelehrter) [41]; and (5) TGF-b1 cDNA
(kindly provided by Dr. H. Moses) [42]. Three blots were
performed for each probe. Autoradiographic signals ob-
tained with 18S cDNA probe served as controls for equal
loading of the gel. Autoradiographs were scanned on a
Bio-Rad GS-700 imaging densitometer (Bio-Rad Labo-
ratories, Inc., Hercules, CA, USA). Changes in mRNA
levels were determined by first correcting for the densit-
ometric intensity of 18S for each sample. For comparison,
this ratio was set at unity for normal control samples, and
other lanes on the same gel were expressed as fold in-
creases over this value.
Western blot
Glomeruli from individual rats were isolated and re-
suspended at 2 × 104 glomeruli/mL in radioimmunopre-
cipitation assay (RIPA) buffer (50 mmol/L Tris/HCl, pH
7.5, 150 mmol/L NaCl, 1% Nonidet P-40, 0.5% deoxy-
cholate, 0.1% SDS, and 1 tablet/5 mL protease inhibitor
mix [Complete, mini; Roche Diagnostics Corp., Indi-
anapolis, IN, USA], 50 lL/5 mL phosphatase inhibitor
cocktail II (Sigma). Glomeruli were homogenized 2 times
on ice by sonication. Each 15-second sonication was fol-
lowed by a 15-second cool down. After 2 centrifuga-
tions at 10,000g for 10 minutes at 4◦C, the supernatant
was stored at −70◦C until analysis. Forty lL of each su-
pernatant was separated by 10% Tris-glycine gel elec-
trophoresis and transferred to a 0.45-lm nitrocellulose
membrane (Millipore, Bedford, MA, USA). Nonspecific
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binding was blocked by 10% nonfat milk powder in Tris-
buffered saline (TBS) for 1 hour at room temperature,
followed by 4◦C overnight incubation with primary an-
tibody [anti–phospho-Smad2; Upstate, Lake Placid, NY,
USA, diluted 1:500 in 5% bovine serum albumin (BSA)
in TBS/0.1% Tween-20 with 0.02% NaN3; or anti–b-actin,
diluted 1:10,000 (Sigma)]. The blot was washed 3 times
for 10 minutes in TBS/0.1% Tween-20. The second an-
tibody, goat antirabbit horseradish peroxidase or goat
antimouse horseradish peroxidase (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA), was incubated at a
dilution of 1:2000 for an additional hour at room temper-
ature, followed by 3 washes as described above. Bound
antibodies were detected by developing the blot in en-
hanced chemiluminescence (ECL)TM Western blotting
detection reagents (Amersham Pharmacia Biotech, Lit-
tle Chalfont, Buckinghamshire, UK) for 1 minute. Quan-
titation of the bands on autoradiograms was performed
using a Bio-Rad GS-700 imaging densitometer. Changes
in p-Smad2 levels were determined by correcting for the
densitometric intensity of b-actin for each sample.
Statistical analysis and calculation of percent reduction
in disease severity
Data are expressed as mean ± SEM. Statistical anal-
ysis of differences between the groups was performed
either by analysis of variance (ANOVA) and subsequent
Student-Newman–Keuls or Dunnett testing for multiple
comparison, or, in the case of PAS scoring, collagen I and
FN immunofluoresence staining, differences between the
groups were tested using analysis of ranks by Kruskal-
Wallis with Dunn’s post analysis. Mean or median values
were considered significantly different when P < 0.05.
The disease-induced increase in a variable was defined
as the mean value for the disease control group minus
the mean value of the normal control group. The per-
cent reduction in disease severity in a treated group was
calculated as:
Disease control group mean − Treated control group mean
Disease control group mean − Normal control group mean ×100
RESULTS
Three questions were asked in these experiments. First,
is 1D11 effective in this model of nephritis and can we de-
termine the maximally effective dose of 1D11? Second,
how does this dose compare with effects seen with maxi-
mal doses of enalapril? And third, can we see additivity of
enalapril and 1D11 when both are administered at maxi-
mally effective doses?
Effect of 1D11
The induction of disease by the administration of OX-
7 produced a rapid accumulation of extracellular matrix
in glomeruli as measured by PAS staining. Representa-
Fig. 1. Effect of increasing doses of 1D11, enalapril, and combinations
of 1D11 and enalapril on the development of glomerulosclerosis. Paraf-
fin sections. Magnification, × 400. Compared with normal rats (A),
glomerular enlargement and significant mesangial matrix deposition
were evident in untreated, disease control (B). These changes were
ameliorated by doses of 1D11 0.01 (C), 0.1 (D), 0.5 (E), 5.0 (F) mg/kg,
and enalapril (G). The best therapeutic effects were achieved by com-
bination therapies Enal+0.5 (H) and Enal+5 (I).
tive glomeruli from this study are shown in Figure 1. The
disease-induced increase in ECM is seen when Figure 1A
(normal control) and Figure 1B (disease control) are
compared. Increasing doses of 1D11 (0.05 mg/kg to
5.0 mg/kg), shown in Figure 1C to F, reveal a clear de-
crease in PAS-positive material with increasing doses of
1D11. To quantify this histologic effect of 1D11 on the ac-
cumulation of ECM, 30 glomeruli per animal were scored
for PAS staining, scores were averaged for each animal,
and then for each group. This analysis, presented graphi-
cally in Figure 2A, indicates that 1D11 produced a dose-
dependent reduction in PAS staining. A moderate but
significant (P < 0.05) decrease of approximately 56% was
seen for PAS staining in rats treated with 0.5 mg/kg 1D11
compared to disease control animals.
In order to determine the contribution of specific ma-
trix proteins to the PAS-positive material immunoflu-
orescent staining for specific glomerular proteins was
performed. Representative glomeruli stained for FN
EDA+ and type I collagen are shown in Figures 3 and 4.
Again, a dramatic increase in staining for matrix proteins
was seen in disease control animals (Figs. 3B and 4B) (up
to 13-fold for collagen and 3.6-fold for FN) compared
to normal control animals (Figs. 3A and 4A). Treatment
with 1D11 produced dose-dependent decreases in the
accumulation of FN EDA+ and collagen I in glomeruli
which are clearly seen when disease control glomeruli
(Figs. 3B and 4B) are compared with increasing doses
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Fig. 2. Effect of increasing doses of 1D11, enalapril, and combinations
of 1D11 and enalapril on matrix score (A), and immunohistochemical
staining for fibronectin EDA+ (B) and collagen I (C). #P < 0.001 dis-
ease control (DC) compared to normal control (NC) group; ∗P < 0.05,
∗∗P < 0.01 and ∗∗∗P < 0.001 treatment groups compared to DC group.
of 1D11 as shown in Figures 3C to F and 4C to F. As
with PAS scores, all staining scores were averaged and
are presented graphically in Figures 2B and 2C. Doses
of 0.5 mg/kg and 5 mg/kg 1D11 reduced both FN EDA+
and collagen I deposition between 32% and 36%, respec-
tively; however, these changes were not significant.
Fig. 3. Immunofluorescence micrographs of fibronectin EDA+. Mag-
nification, × 400. A weak immunoreactivity was observed in nor-
mal glomeruli (A). Remarkably strong intraglomerular staining of fi-
bronectin was found in untreated rats (B). Fibronectin accumulation
was ameliorated by 1D11 treatment 0.01 (C), 0.1 (D), 0.5 (E), 5 (F)
mg/kg, and enalapril (G). The best therapeutic effects were achieved
by combination therapies Enal+0.5 (H) and Enal+5 (I).
Glomerular synthesis of proteins of interest was de-
termined by ELISA on culture supernatants from iso-
lated glomeruli cultured for 48 hours. Again, as shown in
Figure 5, 1D11 treatment caused a dose-related reduction
of these markers of disease. At a 1D11 dose of 5 mg/kg,
FN, PAI-1, and TGF-b1 levels were reduced by 54%,
115%, and 67%, respectively (P < 0.05).
Glomerular mRNA expression of FN EDA+, collagen
I, PAI-1, and TGF-b1 is shown in Figures 6 and 7. Blots
for one gel are shown in Figure 6. The mean ± SE of
densitometry values obtained from scans of 3 gels are
shown graphically in Figure 7. 1D11 treatment reduced
gene expression of FN EDA+ and PAI-1, collagen I, and
TGF-b1 mRNA in a dose-dependent manner. However,
the maximal effect for the inhibition of FN EDA+, col-
lagen I, and TGF-b1 expression was achieved at a dose
of 0.5 mg/kg, with 5 mg/kg appearing to be less effective.
1D11 maximally reduced FN EDA+ expression by 63%,
PAI-1 by 58%, collagen I by 96%, and TGF-b1 by 48%
(Fig. 7A to D, respectively).
Treatment with 1D11 also reduced proteinuria in a
dose-dependent manner. 1D11 at 5 mg/kg maximally re-
duced proteinuria, giving mean urinary proteins of 17.7 ±
2.3 mg/24h, compared to the disease control group (35.1±
8.5 mg/24h). However, for this readout, the control an-
tibody 13C4 mouse IgG1 (5 mg/kg) also reduced pro-
teinuria to 10.2 ± 0.9mg/24h. Hence, it is difficult to
interpret the effect of 1D11 on this variable. The control
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Fig. 4. Immunofluorescence micrographs of type I collagen. Magnifica-
tion, × 400. Tubular basement membrane and Bowman’s capsule were
positively stained with collagen I antibody. Nearly no immunoreactivity
was seen in normal glomeruli (A). Remarkably strong intraglomerular
staining of collagen I was found in untreated disease control rats (B).
Collagen I accumulation was ameliorated to different extents by 1D11
treatments 0.01 (C), 0.1 (D), 0.5 (E), 5 mg/kg (F), and enalapril (G).
The best therapeutic effects were achieved by combination therapies
Enal+0.5 (H) and Enal+5 (I).
antibody, 13C4, had no significant effect on any other
measure of disease (compared to the disease control, data
not shown).
Comparison of the effect of 1D11 and enalapril
From data presented above, it is clear that either 0.5 or
5.0 mg/kg 1D11 show maximal therapeutic effects in this
model. Also, from our previous dose-response study with
enalapril [13], we know that enalapril, at doses greater
than 100 mg/L in drinking water, produces the maximally
obtainable therapeutic response in this model. Thus,
200 mg/L enalapril alone or in combination with 0.5 or
5 mg/kg 1D11 was used to determine the effect of com-
bining these 2 treatments.
The 0.5 mg/kg dose of 1D11 reduced matrix score
by 56%, whereas enalapril alone reduced it by 59%
(Figs. 1E, G, and 2A). This similarity in disease reduc-
tion was seen for most measures of disease. Enalapril or
maximally effective 1D11 (either 0.5 mg/kg or 5 mg/kg)
reduced FN immunostaining by 36% and 36% (Figs. 2B,
3E, and G), collagen I immunostaining by 33% and 34%
(Figs. 2C, 4E, and G), and FN production by 53% and
54%, respectively (Fig. 5A).
In contrast, the therapeutic effect of 1D11 on PAI-
1 production by cultured glomeruli (Fig. 5B) and on
PAI-1 mRNA (Figs. 6 and 7B) appears to be somewhat
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Fig. 5. Effect of increasing doses of 1D11, enalapril, and combinations
of 1D11 and enalapril on glomerular production of fibronectin (A), PAI-
1 (B), and TGF-b1 (C). ∗P < 0.05 compared to normal control (NC)
group; #P < 0.05 compared to disease control (DC) group; ∗∗P < 0.05
compared to enalapril alone; ##P < 0.05 compared to the corresponding
dose of antibody alone.
greater than that seen for enalapril, although statistical
tests did not reach significance for comparisons between
these groups. Similarly, the mRNA analysis suggested
that 1D11 was much more effective in reducing collagen
I mRNA than was enalapril (P < 0.05; Figs. 6 and 7C).
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Fig. 6. A representative Northern blot showing glomerular mRNA ex-
pression of TGF-b1, PAI-1, collagen I, and fibronectin harvested six
days after induction of glomerulonephritis.
Combination of 1D11 and enalapril
It is clear from the data that combining maximally ef-
fective doses of enalapril and 1D11 confers additional
therapeutic benefits compared to either drug given alone.
Combination of enalapril with 1D11 reduced glomeru-
lar matrix accumulation, as measured by PAS staining,
from approximately 59% enalapril alone or 1D11 alone
to 80% for enalapril plus 5.0 mg/kg 1D11 (P < 0.001
compared to disease control animals) (Figs. 1E to I and
2A). The enhanced therapeutic effect of combined treat-
ment with both agents was also seen for FN (Figs. 2B
and 3) and collagen I (Figs. 2C and 4) immunostain-
ing, as well as glomerular production of FN and PAI-1
(Fig. 5A and B). Addition of 1D11 (0.5 mg/kg) to enalapril
further reduced FN production by 25% to a total inhibi-
tion of 77%. In terms of proteinuria, monotherapy re-
duced disease-induced increases in urinary protein by
78%, 74%, and 62% for enalapril, 0.5 1D11, and 5
1D11, respectively. Combination treatment further re-
duced proteinuria to 98% and 99% for 0.5 and 5.0 mg/kg
1D11, respectively, values that did not differ from normal.
Combination treatment had no further effect on PAI-1
production. However, this variable was reduced to lev-
els lower than those of the normal control group, as with
1D11 alone (Fig. 5B). In contrast, as shown in Figure 5C,
the treatment-related reduction in TGF-b1 production
by cultured glomeruli was similar across all treatment
groups, indicating no additive effects of combination on
this readout.
The results obtained for glomerular mRNA levels for
FN, collagen I, TGF-b1, and PAI-1 produced a more
mixed picture than other variables, and one that did not
entirely agree with the results of protein production by
cultured glomeruli (Figs. 6 and 7). FN mRNA levels were
similarly reduced whether enalapril or 1D11 were used
alone and the maximum inhibition of FN mRNA was
achieved with 0.5 mg/kg 1D11, with 5 mg/kg being less ef-
fective. However, the combination of enalapril with 1D11
5 mg/kg appeared to reverse this apparent reduction in
efficacy of 1D11 restoring the inhibition of FN mRNA
production (Fig. 7A). Interestingly, while the therapeutic
effect of enalapril or 1D11 alone resulted in very simi-
lar reductions in PAI-1 mRNA, combination of these 2
drugs appeared to have reversed the effect for PAI-1 mes-
sage (Fig. 7B). Compared to the protein levels measured
in the supernatant, the data suggest that the increase in
PAI-1 mRNA was not translated into PAI-1 protein pro-
duction and secretion into culture supernatant. Collagen
I mRNA was reduced to control levels by 1D11 treatment
alone at both 0.5 and 5 mg/kg; therefore, it is not surpris-
ing that combination of 1D11 and enalapril had no further
effect (Fig. 7C). Finally, the picture for TGF-b1 mRNA
levels is also somewhat mixed (Fig. 7D). While enalapril
or 0.5 mg/kg 1D11 reduced TGF-b1 mRNA by 29% and
48%, respectively, high-dose antibody or combinations
entirely reversed this effect, bringing levels essentially to
those of the disease control group (Fig. 7D). As with PAI-
1 mRNA, this finding was seen only for TGF-b1 mRNA,
and not for TGF-b1 secreted into culture supernatant by
glomeruli. The significance of these mRNA data is there-
fore not fully supportive of the observed protein changes.
The reason for this is unknown.
Studies into possible mechanisms of the additivity of
enalapril and 1D11. Infiltration of macrophages into
injured glomeruli is thought to contribute to disease in
anti-Thy1 nephritis [43]. The results of staining for ED1+
cells of the monocyte/macrophage lineage are shown in
Figure 8. At the 3 low doses of antibody a clear dose-
response is seen, with the number of ED1+ cells being
significantly (P <0.05) reduced by 71% with the 0.5 mg/kg
dose of 1D11. However, at the highest dose of 1D11,
5 mg/kg was less effective, such that the reduction was
only 23% (Fig. 8). Enalapril alone also significantly
(P < 0.05) reduced ED1+ cells by 62%. Interestingly,
as with FN mRNA, combination of both drugs appeared
to prevent the rebound seen with high-dose 1D11 and the
reduction in ED1+ cells was sustained at 70% and 69%
in the two combination groups (Fig. 8).
To study intracellular TGF-b signal transduction, we
analyzed activation of Smad2 using an antibody specif-
ically detecting phosphorylated Smad2 (Fig. 9). Dis-
eased glomeruli have dramatically increased intracellular
p-Smad2 compared to normal control. 1D11 dose-
dependently reduced Smad2 activation, with the maxi-
mal reduction of 75% at the highest dose. Enalapril also
reduced Smad2 activation by 36%. Adding enalapril to
1D11 resulted in a further reduction. 5 mg/kg 1D11 plus
enalapril nearly normalized p-Smad2 levels.
DISCUSSION
The data presented here show that increasing doses
of the TGF-b1, -b2, and -b3 neutralizing antibody 1D11
results in increasing therapeutic efficacy. In this model
of acute renal fibrosis, a dose-dependent reduction of
fibrotic disease is observed until the maximal effect at
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Fig. 8. Effect of increasing doses of 1D11, enalapril, and combinations
of 1D11 and enalapril on immunofluorescent staining for the mono-
cyte/macrophage marker ED1. ∗P < 0.05 compared to normal con-
trol (NC) group; #P < 0.05 compared to disease control (DC) group;
##P < 0.05 compared to the corresponding dose of antibody alone.
0.5 mg/kg 1D11, after which efficacy appears to plateau.
Since some of the measures we employed to assess effi-
cacy were actually less effectively blocked in the group
receiving 5.0 mg/kg 1D11, it is likely that the true maxi-
mally therapeutic dose is between 0.5 and 5.0 mg/kg. The
data suggest that the maximal disease reduction possible
with 1D11 is close to 50%, and that the disease reduc-
tion of 1D11 given alone is comparable to enalapril given
alone.
We have shown that a combination of TGF-b inhibi-
tion with Ang II blockade resulted in an enhanced dis-
ease reduction. Thus, the combination of Ang II blockade
and TGF-b inhibition could represent a major step for-
ward in efforts to halt disease in humans. While we have
previously shown additivity in anti-Thy1 nephritis with L-
arginine supplementation and low protein diet, and also
with angiotensin blockade and low protein diet [44, 45],
both the degree of additivity and the feasibility of the
combination of Ang II blockade and TGF-b inhibition
are clearly superior to the previously used combinations.
A series of studies in the anti-Thy 1 model have shown
that monotherapy with enalapril, losartan, 1% L-arginine
in drinking water, or 6% low protein diet all reduced
markers of fibrotic disease about 50% [11, 43]. In the
present study we add the neutralizing antibody to TGF-
b1, -b2, and -b3, 1D11, to this list. This is a particularly
Fig. 7. Effect of increasing doses of 1D11, enalapril, and combinations
of 1D11 and enalapril on glomerular mRNA levels for fibronectin (A),
PAI-1 (B), collagen I (C), and TGF-b1 (D). Data presented are the
means of densitometric scans of three Northern blots using pooled
mRNA from each group of rats. ∗P < 0.05 compared to normal con-
trol (NC) group; #P < 0.05 compared to disease control (DC) group;
∗∗P < 0.05 compared to enalapril alone; ##P < 0.05 compared to the
corresponding dose of antibody alone.
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Fig. 9. Effect of increasing doses of 1D11, enalapril, and combinations
of 1D11 and enalapril on glomerular p-Smad2 protein as determined
by Western blotting.
important addition because, of the many molecules in-
volved in fibrosis, none has been so consistently or thor-
oughly implicated as over-expression of TGF-b . Here,
even with the potent anti–TGF-b neutralizing antibody
1D11, we see only a maximum 50% reduction in dis-
ease severity. The fact that no single treatment is able to
prevent fibrotic disease suggests that either different
pathways are mediating disease, or that the therapy it-
self stimulates back-up mechanisms to operate. Interest-
ingly, the severity of fibrosis in the rat model of unilateral
ureteral obstruction was also decreased about 50% in
animals where both angiotensinogen genes were dis-
rupted [46]. On the other hand, treatment with a TGF-
b–neutralizing antibody (not 1D11) in a type II diabetic
mouse model (db/db) for 8 weeks reduced glomeruloscle-
rosis by 82% compared to normal littermates, suggesting
that the maximal effectiveness of antibodies may differ
with disease model [27].
It should be noted that a number of studies have shown
additivity of suboptimal doses of various treatments in-
cluding ACEI and AT1RA [45, 47–50]. While combina-
tions of suboptimal doses of two drugs may be clinically
useful to reduce side effects of high doses of one drug, true
additivity, or synergism, can only be shown when maxi-
mally effective doses of at least 1 of 2 drugs are given.
This is the first demonstration of true additivity of ACE
inhibition and TGF-b antibodies. The ability of 1D11 and
enalapril to show additivity when given at maximally ther-
apeutic doses suggests that these drugs act, at least in part,
through different pathways. This is in contrast to results
when enalapril and losartan were combined, and no ad-
ditivity was seen [13], suggesting that these drugs work
though a common pathway.
Inconsistent results in studies such as this are seen
with respect to reductions in either TGF-b mRNA and/or
TGF-b protein. While it might be expected that an asso-
ciation between disease severity and TGF-b expression
would be seen, there are a number of studies where this
was not seen. Here, we did not see a reduction in TGF-
b mRNA with enalapril treatment, although we did in
an earlier study [13]. Similarly, Benigni et al [50], using
lisinopril and 1D11, did not see significant reductions in
glomerular mRNA. Other studies with Ang II blockade
and/or TGF-b antibody therapy have seen significant re-
ductions in TGF-b mRNA [26, 30, 51]. One explanation
for these inconsistencies is the necessity of pooling sam-
ples to obtain adequate RNA for Northern blots, resulting
in reduced power to detect differences. It is clear, how-
ever, that whether TGF-b over-expression is reduced or
not, expression of downstream fibrogenic molecules, such
as collagen I and FN, is generally significantly reduced.
To help clarify the mixed picture of TGF-b expression
in this and other studies, we looked further into TGF-b
signal transduction system. Using p-Smad2 as an activa-
tion marker, we found 1D11 dose-dependently reduced
TGF-b signal transduction, and so did maximally effec-
tive doses of enalapril. Combination therapy resulted in
further reduction of p-Smad2 compared to monother-
apy. This result is consistent with the reductions seen for
other measures of disease severity. It is probable that the
enalapril effect on Smad activation is due to blocking Ang
II–induced up-regulation of TGF-b or TGF-b receptor
expression [52–55].
An interesting finding in the study presented here is
that the 1D11 dose response is modulated by the addition
of enalapril. Reversal of the therapeutic effect of 1D11
on matrix score (Fig. 2A), FN mRNA (Fig. 7A), colla-
gen I mRNA (Fig. 7C), and TGF-b1 mRNA (Fig. 7D)
was seen at the highest dose of 1D11 (5.0 mg/kg). While
this reversal was often marginal for all but FN, the re-
sults do hint that more complete inhibition of TGF-b
may be less effective at treating disease. This is most
clearly seen in Figure 8, where the highest dose of 1D11,
5 mg/kg, is less effective at reducing ED1+ cell influx
than a lower dose of this agent. Interestingly, a similar
effect on monocyte/macrophage cells with the 5.0 mg/kg
dose of 1D11 was recently reported in the puromycin
nephropathy model [abstract; Ma LJ et al, J Am Soc
Nephrol 12:2001:819A]. In the present study, the ther-
apeutic effect was also reduced with this dose of 1D11.
Both Ang II and TGF-b play important roles in recruit-
ment of activated macrophages to the site of injury. These
activated macrophages are thought to release chemotac-
tic and profibrotic factors. TGF-b , however, has dual ef-
fects on macrophages. It strongly attracts macrophages
and at the same time inhibits activated macrophage func-
tion by reducing the production and release of other
chemotactic and inflammatory factors [56–58]. It is pos-
sible that increasing doses of 1D11 decrease macrophage
infiltration initially, but as more TGF-b is neutralized,
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escape from TGF-b inhibition may lead to release of
agents that further recruit macrophages. While the re-
duction of effect at higher doses of 1D11 and the possible
role of macrophages in this observation requires further
study, it is very interesting that combination of high-dose
1D11 with enalapril appears to reverse this tendency to
rebound for all variables, except for TGF-b1 mRNA. This
supports the notion that combination of Ang II blockade
with TGF-b antibodies will not only provide greater ther-
apeutic benefit than currently available therapies, but that
any potential negative consequences may be ameliorated
by this drug combination.
Finally, it is noteworthy that TGF-b antibody treat-
ment did not cause any noticeable side effects. This is not
surprising since this short-term experiment lasted only
6 days. Other long-term studies with TGF-b antibody,
including 4 publications with the mouse monoclonal an-
tibody, 1D11 used here [27, 28, 30, 50, 51, 59], reported
no safety problems with this therapy.
CONCLUSION
The study presented here demonstrates a clear dose-
dependent therapeutic response for the TGF-b1, -b2, and
-b3 neutralizing antibody, 1D11. The maximal therapeu-
tic effect of monotherapy is close to 50% disease reduc-
tion, whether the therapy is Ang II blockade or TGF-b
inhibition. Finally, and most importantly, the data show an
additional reduction in disease severity when maximally
effective doses of enalapril are combined with TGF-b an-
tibody, a finding that may stimulate human trials of such
combinations and eventually better therapy for human
fibrotic kidney disease.
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